UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549

FORM 8-K

CURRENT REPORT PURSUANT
TO SECTION 13 OR 15(D) OF THE
SECURITIES EXCHANGE ACT OF 1934

Date of report (Date of earliest event reported): February 23, 2016

SECOND SIGHT MEDICAL PRODUCTS, INC.
(Exact Name of Registrant as Specified in Its Charter)

California
(State or Other Jurisdiction of Incorporation)

333-198073	**02-0692322**
(Commission File Number)	(IRS Employer Identification No.)

12744 San Fernando Road, Suite 400
Sylmar, California 91342
(Address of Principal Executive Offices)

(818) 833-5000
(Registrant's Telephone Number, Including Area Code)

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

ITEM 7.01. **REGULATION FD DISCLOSURE**

A copy of a slide presentation that Second Sight Medical Products, Inc. ("Second Sight ") intends to use during presentations made before groups and in hosting one-on-one meetings with individuals at the RBC Capital Markets 2016 Global Healthcare Conference in New York City on February 23, 2016 and at BTIG 2016 Annual MedTech Conference in Snowbird, Utah on February 25, 2016 (the "Presentation Materials"), is attached to this Current Report on Form 8-K as Exhibit 99.1 and is incorporated by reference herein. The Presentation Materials speak as of the date of this Current Report on Form 8-K. While Second Sight may elect to update the Presentation Materials in the future or reflect events and circumstances occurring or existing after the date of this Current Report on Form 8-K, Second Sight specifically disclaims any obligation to do so. Additionally, Second Sight has posted a link to the live and replay presentations given by Second Sight at the RBC Capital Markets Conference on the Investor Relations section of Second Sight's website: http://investors.secondsight.com. The information contained in this Item 7.01 and Exhibit 99.1 hereto shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by reference in such a filing.

ITEM 9.01 FINANCIAL STATEMENTS AND EXHIBITS

Exhibit No. Description

99.1 Second Sight Medical Products, Inc. Investor Presentation dated February 2016

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: February 22, 2016

SECOND SIGHT MEDICAL PRODUCTS, INC.

/s/ Thomas B. Miller
By: Thomas B. Miller
Chief Financial Officer

Exhibit 99.1

Second Sight

NASDAQ: EYES

Investor Presentation

2016

Forward Looking Statements

NASDAQ: EYES

This presentation contains certain forward-looking information about Second Sight that is intended to be covered by the safe harbor for "forward-looking statements" provided by the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts. Words such as “anticipate,” “believe,” “estimate,” “expect,” “intend,” “may,” “plan,” “predict,” “project,” “target,” “potential,” “will,” “would,” “could,” “should,” “continue,” “strong,” “up coming,” and similar expressions are intended to identify forward-looking statements. These statements include, but are not limited to, statements regarding our ability to successfully develop and commercialize our products; our ability to expand our long-term business opportunities; financial projections and estimates and their underlying assumptions; and future performance.

In this document, we refer to information regarding potential markets for products and other industry data. We believe that all such information has been obtained from reliable sources that are customarily relied upon by companies in our industry. However, we have not independently verified any such information.

Forward-looking statements may address the following subjects among others: expected products, applications, customers, technologies and performance, coverage and insurance reimbursements, results of clinical studies, success of research and development and our expectations concerning our business strategy. Forward-looking statements involve inherent risks and uncertainties which could cause actual results to differ materially from those in the forward-looking statements, as a result of various factors including those risks and uncertainties referred to in the Risk Factors and in Management's Discussion and Analysis of Financial Condition and Results of Operations sections of our Annual Report on Form 10-K as filed on March 17, 2015 and our other reports filed from time to time with the Securities and Exchange Commission. The audience is cautioned not to place undue reliance on these forward-looking statements that speak only as of the date hereof, and we do not undertake any obligation to revise and disseminate forward-looking statements to reflect events or circumstances after the date hereof, or to reflect the occurrence of or non-occurrence of any events.

Leader in Restoring Vision through Technology

NASDAQ: EYES

Leading Platform Technology for the Blind

- First and only FDA-approved neurostimulation device for the blind on the market
- 348 patents granted; 155 pending
- 16+ years of R&D

Significant Addressable Market

- 8+ million people blind due to unpreventable causes
- Targeting RP, AMD and other untreatable causes of blindness

Demonstrated Commercial Execution

- ONLY retinal prosthesis approved by the FDA
- Regulatory clearance in the EU and Turkey
- 33 Implanting centers worldwide

Proven Reimbursement Success

- 4 of 12 MAC regions issued positive coverage decisions
- CMS reimbursement in 16 states
- Case-by-case wins in US, EU & ROW

Financial Position

- $21.7 million in cash as of 9/30/15
- No debt

Targeting Large Addressable Market

NASDAQ: EYES

Of the 39M people worldwide that are legally blind, 8M+ are due to untreatable causes

5.8 M	**Other Untreatable Causes** Includes glaucoma, infection, etc.
2.0 M	**Age-Related Macular Degeneration (AMD)** Ongoing clinical trial in dry AMD in the U.K.
0.4M	**Retinitis Pigmentosa (RP)** Commercialization today is a subset of this population*

Worldwide Patients Who Are Legally Blind



Second Sight

*Current regulatory approvals are for vision levels worse than legal blindness.

Argus® II – Restoring Useful Vision

NASDAQ: EYES

16+ years of R&D

170+ implants since 2002

Key Benefits:

- Improved orientation and mobility
- Enhanced connection to surroundings
- Improved Quality of Life
- Enhanced ability to perform daily activities

http://www.bloomberg.com/news/videos/2015-05-21/bionic-eyes-give-second-sight-to-the-blind

Argus II Platform Neurostimulation Technology

NASDAQ: EYES

Hermetic Package
Smallest size & largest number of individually programmable electrodes

Patented Electrode Material Enables Small Size
Facilitates smaller & more concentrated electrodes in given area

Long-Term Reliability
Safe bio-interface & 10+ year lifetime[1]

The Argus II Platform

Video Processing Unit (VPU)

Argus II Glasses

Argus II Implant

60 electrodes

Strong Patent Protection: 348 patents; 155 pending patent applications

Safe Bio-Interface + Long-term Reliability + Demonstrated Benefit

1) 10+ years of lifetime use in accelerated in vitro testing and 8.5+ years use in real time in patients under active stimulation and normal use conditions

Major Awards & Recognition

NASDAQ: EYES

Cleveland Clinic
Top Medical Innovation of 2014

MD+DI
2013 Medical Device Manufacturer of the Year

CNN
The CNN 10: Inventions Of 2013

TIME
The 25 Best Inventions of 2013

EDISON AWARDS
2014 Gold Winner—Science/Medical Category

POPULAR SCIENCE
2013 Innovation of the Year

50 SMARTEST COMPANIES
The 50 Smartest Companies for 2014

Inc.
The 25 Most Audacious Companies 2013

WORLD ECONOMIC FORUM
Technology Pioneer 2014

Progress Since November 2014 IPO

NASDAQ: EYES

Q4 '14	• NASDAQ IPO raises $32M • 18 implanting centers certified at year end
Q1 '15	• First implants in Austria, Turkey & Spain
Q2 '15	• Appointed Will McGuire as CEO • Entered into distribution agreement in Saudi Arabia • Announced positive long-term results from multi-center clinical trail • Initiated enrollment in Dry-AMD trial • Implanted Orion I in animal study
Q3 '15	• Added MAC coverage in 10 states for a total of 16 states
Q4 '15	• FY 2015: Expanded to 33 implanting centers • FY 2015: Completed 75 implants

Our Strategy

NASDAQ: EYES

- Grow Commercial Footprint & Expand Reimbursement Coverage
- Enhance Argus II Technology
- Enter AMD Market
- Expand into Direct Cortical Stimulation

Goal: Build organizational foundation supporting operational excellence and sustained long-term growth

Growing Commercial Footprint

NASDAQ: EYES

- 33 centers of excellence worldwide
- Direct sales: 9 field sales reps & clinical specialists
- Distribution partners: Spain, Turkey, Saudi Arabia & Argentina
- New markets under consideration in Asia/Pacific & Latin America

Goal: Add new centers where we have established reimbursement

Expanding Reimbursement Coverage

NASDAQ: EYES

24 Medicare Advantage or Private Insurer Plans
- approved case-by-case
- $144K ASP in 2015

89% Pre-Authorizations
approved by Medicare Advantage in 2015

CMS Coverage
4 of 12 MAC Regions issued coverage policies (33% of U.S. population)

CMS Coding
established for device & surgical procedure

CMS Pricing
2016: $95K for device & surgical procedure

European Coverage
in France, Germany & 2 regions of Italy

Forfait Innovation
Two-year post-market study in France (18 subjects + 18 more funded)

Goal: Continue reimbursement momentum

Second Sight

1) For the first nine months of fiscal 2015, ended on September 30, 2015, implants in patients covered by Medicare fee for service accounted for only 13% of our global implant volume.

Enhancing Argus II Technology

NASDAQ: EYES

Current Indication:

- Bare or no light perception in RP patients in U.S.
- Severe to profound vision loss from outer retinal degeneration in Europe

Targeting:

- Broader RP population with less vision loss

Key Enhancements

External Hardware Upgrade	Advanced Image Processing Software	Retina Stimulation Protocols
• 25x VPU higher processing power	• Better definition of objects	• Improved resolution by adjusting pulses, waves, steering to/of electrodes

Goal: Continue to enhance the Argus II for RP so patients can perform functional tasks & be more independent, leading to a better quality of life

Entering AMD Market

NASDAQ: EYES

Dry AMD Pilot Study

- 5 subject clinical trial in the UK initiated June 2015
- 4 of 5 patients enrolled as of Dec. 31, 2015
- Patients to be evaluated over six month period to determine next steps and go forward strategy

Normal Vision | **Vison with Dry AMD**

Goal: Determine the utility of the Argus II System for use in patients suffering from dry AMD

Expanding into Direct Cortical Stimulation

NASDAQ: EYES



- Leverage existing Argus II technology
- Bypass the optic nerve and directly stimulate the visual cortex
- Fully active animal implants expected by Q1 2016
- Begin clinical trials in 1H 2017

Goal: Restore vision to 5.8 million patients blinded by trauma, glaucoma & optic nerve disease, among other untreatable causes

Patent Protection

NASDAQ: EYES

Large portfolio creates significant barriers to entry

348 Patents & 155 Patent applications pending

USPTO	
Grants	252
Pending Applications	78
Foreign Offices	
Grants	96
Pending Applications	77



Competitive Landscape

NASDAQ: EYES

Dominant industry position for the foreseeable future

- **Significant first mover advantage with 5+ year lead time in the U.S.**
- Several difficult engineering challenges were overcome during the development of the product (i.e. device reliability, extended lifetime & safe/effective bio-interface)

Therapeutic Approaches to Vision Loss

Treatment
Retinal Prosthesis
Transplants
Stem Cells
Gene Therapy
Optogenetics
Nutritional Therapy
Implantable Telescope

Retinal Prosthesis Competitors

	Regulatory Approval		In Market
	CE	FDA	
retina implant *(Germany)*	✔	✖	✖
Pixium Vision *(France)*	✖	✖	✖
Eye & Health Care NIDEK CO., LTD. *(Japan)*	✖	✖	✖
NanoRetina *(Israel)*	✖	✖	✖

Select Financials

NASDAQ: EYES

(USD $ in Thousands)	9M 2015	9M 2014	FY 2014	FY 2013
Revenue	$6,588	$1,878	$3,398	$1,565
Gross Profit	2,966	(259)	(160)	(4,064)
Net Loss	(14,545)	(21,624)	(35,201)	(22,968)
Non-GAAP Adjusted Net Loss*	(12,394)	(13,840)	(19,401)	(17,185)

(USD $ in Thousands)	Sep 30, 2015		Dec 31, 2014	
Cash, cash equivalents & investments	$21,669		$34,619	
Outstanding Debt	**$0**		**$0**	

*Non-GAAP adjusted net loss for the nine months ended September 30, 2015 and 2014, and FY 2014 and FY 2013 excludes non-cash expenses including stock-based compensation, interest expense on convertible notes, amortization of discount on convertible notes and write-off of unamortized discount on convertible notes.

Investment Highlights

NASDAQ: EYES

- **First mover advantage** with leading Argus II platform technology to restore vision to the blind
  - Only U.S. FDA approved retinal prosthesis
  - 33 implanting centers & 170+ implants worldwide
- **Successful execution of reimbursement** strategy in U.S. & Europe
- Targeting **significant addressable market** of 8M+ people
- Securing our market leading position with **strong patent protection**
- **Financial flexibility** to execute strategic objectives (strong balance sheet & no debt)

Contact

NASDAQ: EYES

Second Sight Medical Products, Inc.
12744 San Fernando Road
Suite 400
Sylmar, CA 91342
Main: 818-833-5000
www.secondsight.com

Robert Greenberg
Chairman
Direct: 818-833-5050
bob@secondsight.com

Retail Investor Relations
Matt Hayden
Chairman
MZ North America
Direct: 949-259-4986
Matt.Hayden@mzgroup.us

Institutional Investor Relations
Lisa Wilson
President
In-Site Communications, Inc.
Direct: 212-452-2793
lwilson@insitecony.com